CLSN Investor Alert - Bronstein, Gewirtz & Grossman, LLC Notifies Celsion Corporation Shareholders With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: December 28, 2020

NEW YORK, Nov. 3, 2020

("Celsion" or "the Company") (NASDAQ: CLSN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Celsion securities between November 2, 2015 to July 10, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/clsn.    

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. 

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) defendants had significantly overstated the efficacy of ThermoDox; (2) the foregoing significantly diminished the approval and commercialization prospects for ThermoDox; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/clsn or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Celsion you have until December 28, 2020 to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.  Attorney advertising. Prior results do not guarantee similar outcomes.